Anthony DiMoro 27 August 2024

Study Shows That Medicare Coverage of Novo’s Semaglutide for CVD Could Cost $145 Billion Per Year

A new study is showing that providing Part D Medicare coverage for Novo Nordisk’s semaglutide to reduce cardiovascular disease risk in certain patients could cost the United States Government around $145 billion annually, according to new research published Tuesday in the Annals of Internal Medicine. Semaglutide, which is branded as Ozempic for type 2 diabetes and…

Anthony DiMoro 27 August 2024

Medicare Reimbursement For Breast Surgery Showing Steady Decline

Breast surgery is no long and exception in regards to Medicare reimbursement rates according to new research, via General Surgery News. Breast reduction surgery, which is also known as reduction mammaplasty, involves removing skin and tissue from the breasts, then reshaping them to a smaller size, a surgery that has been on the rise since the…

Anthony DiMoro 21 August 2024

Medicaid Overtakes Medicare Advantage in Q2 Earnings

Despite the challenges in both Medicaid and privately run Medicare Advantage, the major insurers still posted sizeable earnings during Q2, much of which was helped by the health services divisions. According to Healthcare Dive, Medicare Advantage and safety-net Medicaid plans are seeing their profitability shrink amid ongoing operational pressures which is a flip from what…